Abstract:ID 98732 Poster Board 486 Addiction to tobacco and nicotine products remains a leading cause of disease and death worldwide, and an increasing number of never-smokers are being exposed to nicotine via e-cigarettes. With only a few moderately efficacious smoking-cessation therapeutics available, achieving long-term abstinence from nicotine addiction is an unattainable goal for millions. The role of brain nicotinic acetylcholine receptors (nAChRs) in nicotine's behavioral effects leading to tobacco addiction is well recognized. However, the neurobiological basis underlying the role of specific nAChRs in nicotine's behavioral effects remains poorly understood. Our recently published findings have emphasized the role of the high-sensitivity isoform of the α4β2 nAChRs (the HS (α4)2(β2)3 nAChR) in nicotine-associated behavior. Therefore, our current efforts are focused on the development of novel positive allosteric modulators (PAMs) that selectively target the HS (α4)2(β2)3 nAChR for in vivo applications to probe the function of this major nAChR subtype as well as for potential therapeutic applications as smoke-cessation aid. Unlike classical nAChR agonists, which bind at the evolutionary conserved ACh binding site, PAMs bind to sites that are less conserved and potentially unique to the HS (α4)2(β2)3 nAChR making the subtype selectively more attenable. In addition, PAMs act only in the presence of the endogenous neurotransmitter, minimizing tonic activation, desensitization, receptor upregulation, and alteration in the pattern of cholinergic synaptic transmission seen with nAChR agonists. Using three nAChR PAM pharmacophores and computational ligand docking predictions, we synthesized a series of derivatives and examined their nAChR PAM activities (ability to enhance ACh-induced current responses) in vitro . Candidates with potent and efficacious in vitro HS (α4)2(β2)3 nAChR PAM activities are currently being evaluated for their ability to reduce nicotine self-intake and withdrawal symptoms in mice.

Affinity of Nicotinoids to a Model Nicotinic Acetylcholine Receptor (nAChR) Binding Pocket in the Human Brain

Affinity of nicotinoids to a model nicotinic acetylcholine receptor (nAChR) binding pocket in the human brain

Ligands for Brain Cholinergic Channel Receptors: Synthesis and in Vitro Characterization of Novel Isoxazoles and Isothiazoles As Bioisosteric Replacements for the Pyridine Ring in Nicotine

Optimizing positive allosteric modulators to selectively target the high sensitivity 23 nicotinic acetylcholine receptor

Alcohol and Nicotinic Acetylcholine Receptors

Evaluation of (S)-T1 and (S)-T2 ligands targeting α3β4 nAChR as potential nicotine addiction pharmacotherapy

Insights into nicotinic receptor signaling in nicotine addiction: Implications for prevention and treatment.

Molecular docking and dynamic simulation studies of α4β2 and α7 nicotinic acetylcholine receptors with tobacco smoke constituents nicotine, NNK and NNN

From Α4β2 Nicotinic Ligands to the Discovery of Σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design.

Roles Of Nicotinic Acetylcholine Receptor Beta Subunits In Function Of Human Alpha 4-Containing Nicotinic Receptors

Differential Regulation of Mesolimbic Α3/α6β2 and Α4β2 Nicotinic Acetylcholine Receptor Sites and Function after Long-Term Oral Nicotine to Monkeys

Scaffold Ranking and Positional Scanning Utilized in the Discovery of Nachr-Selective Compounds Suitable for Optimization Studies

Biososteric Replacement in the Design and Synthesis of Ligands for Nicotinic Acetylcholine Receptors

Synthesis and Nicotinic Acetylcholine Receptor Binding Affinities of 2- and 3-Isoxazolyl-8-azabicyclo[3.2.1]octanes.

Highly selective and potent α4β2 nAChR antagonist inhibits nicotine self-administration and reinstatement in rats.

Insights into the Structural Determinants Required for High-Affinity Binding of Chiral Cyclopropane-Containing Ligands to Α4β2-Nicotinic Acetylcholine Receptors: an Integrated Approach to Behaviorally Active Nicotinic Ligands

Molecular Recognition Properties of Nicotinic Ligands Determining Selectivity Between Insect and Mammalian Receptors

QSAR Study of a Large Set of 3-Pyridyl Ethers As Ligands of the Α4β2 Nicotinic Acetylcholine Receptor

Chemical Biology of the Nicotinic Insecticide Receptor

Exploring the binding energy profiles of full agonists, partial agonists, and antagonists of the α7 nicotinic acetylcholine receptor

SR9883 is a novel small-molecule enhancer of α4β2* nicotinic acetylcholine receptor signaling that decreases intravenous nicotine self-administration in rats